Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)

被引：0
|
作者：
Quintyne, K. I. [1 ]
Woulfe, B. [2 ]
Dee, A. [3 ]
Gupta, R. [2 ]
机构：
[1] NCCP, Community Oncol, Dublin, Ireland
[2] Midwestern Reg Hosp, Med Oncol, Limerick, Ireland
[3] HSE Midwest, Publ Hlth, Limerick, Ireland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1031P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    [J]. PharmacoEconomics, 2018, 36 : 505 - 505
  • [22] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for early breast cancer
    Wardley, Andrew M.
    Cameron, David A.
    Bell, Richard
    Erny, Samuel
    Cohen, Carole
    Geary, Una
    Walzer, Stefan
    Gyldmark, Marlene
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 95 - 96
  • [23] Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
    Goldvaser, Hadar
    Korzets, Yasmin
    Shepshelovich, Daniel
    Yerushalmi, Rinat
    Sarfaty, Michal
    Ribnikar, Domen
    Thavendiranathan, Paaladinesh
    Amir, Eitan
    [J]. JNCI CANCER SPECTRUM, 2019, 3 (02)
  • [24] Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    The, Due Ong
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 815 - 824
  • [25] Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer
    Fagnani, Francis
    Colin, Xavier
    Arveux, Patrick
    Coudert, Bruno
    Misset, Jean-Louis
    [J]. BULLETIN DU CANCER, 2007, 94 (7-8) : 711 - 720
  • [26] Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
    Schwartz, Naomi R. M.
    Flanagan, Meghan Rose
    Babigumira, Joseph B.
    Steuten, Lotte Maria Gertruda
    Roth, Joshua A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment
    Genuino, Anne Julienne
    Gloria, Mac Ardy Junio
    Chaikledkaew, Usa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1001 - 1010
  • [28] Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+in Vietnam
    Nguyen, Anh Quynh
    Tran, Oanh Thi Mai
    Nguyen, Phuong Khanh
    Nguyen, Ha Thu
    [J]. PLOS ONE, 2024, 19 (03):
  • [29] Systemic therapy for HER2-positive early-stage breast cancer
    Mathew, Aju
    Romond, Edward H.
    [J]. CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 106 - 116
  • [30] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
12345